Jun. 23 at 5:08 PM
$LAB The sale of Soma Logic is an exceptionally smart move — and a reflection of the seasoned leadership guiding Standard BioTools. The Illumina partnership is a major win, validating what was once a controversial acquisition.
The SomaLogic deal not only delivered meaningful cash — it showcased this team’s ability to unlock value from underappreciated assets, secure a 10-year royalty stream, and partner with a category leader.
Now, with a simplified structure, disciplined operations, and
$550M+ in expected cash, they’re positioned to make two to three more strategic acquisitions. Backed by strong institutional investors like Casdin Capital, they have the clarity, capital, and conviction to reshape the proteomics tools space.
They’ve already proven they’re good. And management teams like this don’t just fade away — they build the kinds of companies others want to own. With a bit of luck, this could be a 10-bagger by 2030.
